Product Description.:
Drops , off-white
Opaque
BESIVANCE is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: CDC coryneform group G, Corynebacterium pseudodiphtheriticum,* Corynebacterium striatum,* Haemophilus influenzae, Moraxella lacunata,* Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis,* Staphylococcus lugdunensis,* Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*
Important Risk Information about BESIVANCE?
Besivance should not be injected into the eye or used systemically. As with other anti-infectives, prolonged use of Besivance may result in overgrowth of non-susceptible organisms leading to super-infection. Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with Besivance. At the first sign of an allergic reaction, patients should discontinue use immediately and contact their physician.
The most common adverse events in clinical trials were conjunctival redness, blurred vision, eye pain, eye irritation, eye pruritus and headache, reported in approximately 1-2% of patients one year and older. Safety and effectiveness in infants below one year of age have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
